MOBERG PHARMA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.04 SEK | +7.65% |
|
-1.80% | +64.74% |
| May. 14 | Moberg Pharma AB Elects Jonas Ekblom as Board Member | CI |
| May. 07 | Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 337.9 | 143.1 | 228 | 425 | 650.4 | - | - |
| Enterprise Value (EV) 1 | -557.6 | 143.1 | 228 | 425 | 411.4 | 451.4 | 650.4 |
| P/E ratio | 0.58 x | 15.7 x | -11 x | -11.4 x | -3.32 x | -4.65 x | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 21.7 x | 2.83 x | 1,101 x | - | 108 x | 15.5 x | 6.57 x |
| EV / Revenue | -35.8 x | 2.83 x | 1,101 x | - | 68.6 x | 10.7 x | 6.57 x |
| EV / EBITDA | 186 x | - | -12.9 x | -16.8 x | -11.4 x | -21.5 x | 22.4 x |
| EV / FCF | - | - | - | -2.7 x | -5.71 x | -11.3 x | 108 x |
| FCF Yield | - | - | - | -37% | -17.5% | -8.86% | 0.92% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,867 | 1,986 | 9,827 | 27,961 | 27,961 | - | - |
| Reference price 2 | 181.0 | 72.05 | 23.20 | 15.20 | 23.26 | 23.26 | 23.26 |
| Announcement Date | 9/27/19 | 2/9/21 | 2/7/23 | 2/13/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 15.55 | 50.49 | 0.207 | - | 6 | 42 | 99 |
| EBITDA 1 | -3 | - | -17.64 | -25.36 | -36 | -21 | 29 |
| EBIT 1 | -4.22 | - | -20.23 | -27.46 | -37 | -24 | 6 |
| Operating Margin | -27.13% | - | -9,771.01% | - | -616.67% | -57.14% | 6.06% |
| Earnings before Tax (EBT) 1 | -5.065 | - | - | -25.42 | -36 | -24 | 7 |
| Net income 1 | 558.8 | - | -15.71 | -21.09 | -29 | -22 | 5 |
| Net margin | 3,592.74% | - | -7,589.37% | - | -483.33% | -52.38% | 5.05% |
| EPS 2 | 313.5 | 4.600 | -2.100 | -1.330 | -7.000 | -5.000 | - |
| Free Cash Flow 1 | - | - | - | -157.3 | -72 | -40 | 6 |
| FCF margin | - | - | - | - | -1,200% | -95.24% | 6.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 20.69% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 120% |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 9/27/19 | 2/9/21 | 2/7/23 | 2/13/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 895 | - | - | - | 239 | 199 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -157 | -72 | -40 | 6 |
| ROE (net income / shareholders' equity) | -1.1% | - | - | -3% | -4% | -3% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 32.4 | - | - | - | - | - | - |
| Capex / Sales | 208.28% | - | - | - | - | - | - |
| Announcement Date | 9/27/19 | 2/9/21 | 2/7/23 | 2/13/24 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +53.03% | 62.5M | |
| +43.64% | 754B | |
| +39.42% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- MOB Stock
- Financials Moberg Pharma AB
